M
Medifab
Biomaterial and 3D bioprinting for tissue regeneration
About Medifab
Medifab is a bio-health care company developing next-generation prosthetics for reconstruction and correction. The company, based in Seoul, South Korea, develops, produces, and supplies prostheses that can replace silicon and fillers by utilizing biomaterials for tissue repair and 3D printing technologies. Founded in January 2016 by CEO Misun Cha, Medifab has focused on continuous research and development.
The company's main business areas include biomaterials for tissue repair, evaluation models to replace animal testing, and 3D printed medical devices. Its product lineup includes the 'Cellrix' 3D culture system and viability assay kits, 'Organo cube' 3D bio-printers, and 'Husteon' 3D printing medical devices. Medifab has established a biotechnology research center and has secured multiple patents for its technologies, including methods for manufacturing hydrogel supports and 3D cell culture supports. Medifab collaborates with specialized hospitals and has received investments from firms such as DY Co., Ltd., Shinhan Venture Investment, and IBK Capital.
The business model centers on manufacturing and supplying these advanced medical products. Medifab aims to provide innovative medical devices by leveraging its core technologies and partnerships with research institutions like Seoul National University. The company received approval for medical device manufacturing in December 2019 and has been recognized for its technology by the South Korean Ministry of Trade, Industry and Energy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 52.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, 3D Printing, Biotechnology, medical implants, Surgery, Stem Cells, Biotech and Pharma, DT and LS, science-based
- Technology
- 3D Technology, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2025 | $17M | $67M | Mirae Asset Capital · Murex Partners · Sneak Peek Investments, Inc. · Mirae Asset Venture Investment | ↗ |
| SERIES AEquity / VC | Oct 2021 | $3.4M | $13M | Shinhan Capital | — |
Growth signals
Latest recorded traffic for Medifab is 3.2K monthly website visits, up 77.8% over the last three months. Medifab's team grew 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
IBK Securities
Series A10 investors entered at this stage
- SCShinhan Capital
Sneak Peek Investments, Inc.
Mirae Asset Capital- MPMurex Partners
Mirae Asset Venture Investment- DPDaily Partners
- PPPathway Partners
- QMQuad Asset Management
Hanwha Investment & Securities- BSBNK Securities
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medifab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medifab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.